Defining the Ablative Dose for Y-90 TARE

Defining the Ablative Dose for Y-90 TARE
Conditions: HCC – Hepatocellular Carcinoma

Interventions: Other: Yttrium-90 Radiation Segmentectomy (Y90 RS) using glass microspheres

Sponsors: Northwestern University; Radiological Society of North America; Northwestern University Feinberg School of Medicine; Robert H. Lurie Cancer Center

Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

May 15, 2026Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments